ArticleAnnals of surgical oncology2025
Low TIF1γ Expression is Associated with Cancer Aggressiveness and Shorter Recurrence-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Suppression of TRIM33 and SMAD4 Indicates a Possible Tumor-Suppressive Role in Esophageal Squamous Cell Carcinoma.Digestive diseases and sciences · 2026Article
- Surgical treatment strategy for elderly patients with esophageal cancer in the new era: a narrative review.Surgery today · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) is a significant cause of cancer-related death despite advances in multidisciplinary treatment. Transcriptional intermediary factor 1 γ (TIF1γ) has been known to be involved in tumorigenesis and epithelial-mesenchymal transition (EMT), which are linked to cancer aggressiveness and therapeutic resistance. However, its role in ESCC remains unclear. Therefore, we investigated the expression significance and function of TIF1γ in ESCC.
methodsWe used immunohistochemical analysis to investigate the clinical significance of tumoral TIF1γ expression in 131 patients with ESCC. We also performed in vitro analysis using ESCC cell lines to evaluate the effects of TIF1γ suppression on EMT marker expression, migration ability, and 5-fluorouracil (5-FU) sensitivity.
resultsThe TIF1γ protein was mainly expressed in the nuclear ESCC cells. Low nuclear TIF1γ expression was associated with the progression of tumor depth and frequent recurrence. Low TIF1γ expression was an independent predictor of recurrence in ESCC. Moreover, suppression of TIF1γ facilitated EMT-like changes, such as high migration ability, E-cadherin suppression, vimentin induction, and 5-FU resistance of ESCC cells.
conclusionsTIF1γ may be a promising biomarker for predicting patients with ESCC at high risk of recurrence. Therapeutic strategies that induce TIF1γ expression are expected to improve the chemosensitivity and prognosis of high-risk patients with ESCC who have low TIF1γ.
Indexed as
Identifiers
40208493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.